Kiromic Biopharma Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.51
- Today's High:
- $1.63
- Open Price:
- $1.56
- 52W Low:
- $1.43
- 52W High:
- $15.3
- Prev. Close:
- $1.54
- Volume:
- 19493
Company Statistics
- Market Cap.:
- $2.15 million
- Book Value:
- -5.352
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -91.94%
- Return on Equity TTM:
- -1129.81%
Company Profile
Kiromic Biopharma Inc had its IPO on 2020-10-16 under the ticker symbol KRBP.
The company operates in the Healthcare sector and Biotechnology industry. Kiromic Biopharma Inc has a staff strength of 31 employees.
Stock update
Shares of Kiromic Biopharma Inc opened at $1.56 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.51 - $1.63, and closed at $1.58.
This is a +2.6% increase from the previous day's closing price.
A total volume of 19,493 shares were traded at the close of the day’s session.
In the last one week, shares of Kiromic Biopharma Inc have slipped by -13.28%.
Kiromic Biopharma Inc's Key Ratios
Kiromic Biopharma Inc has a market cap of $2.15 million, indicating a price to book ratio of 15.106 and a price to sales ratio of 0.
In the last 12-months Kiromic Biopharma Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-22190000. The EBITDA ratio measures Kiromic Biopharma Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Kiromic Biopharma Inc’s operating margin was 0% while its return on assets stood at -91.94% with a return of equity of -1129.81%.
In Q2, Kiromic Biopharma Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Kiromic Biopharma Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-39.68 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Kiromic Biopharma Inc’s profitability.
Kiromic Biopharma Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.1629. Its price to sales ratio in the trailing 12-months stood at 0.
Kiromic Biopharma Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $13.64 million
- Total Liabilities
- $18.70 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Kiromic Biopharma Inc ended 2024 with $13.64 million in total assets and $0 in total liabilities. Its intangible assets were valued at $13.64 million while shareholder equity stood at $-6294800.00.
Kiromic Biopharma Inc ended 2024 with $0 in deferred long-term liabilities, $18.70 million in other current liabilities, 1176.00 in common stock, $-114012200.00 in retained earnings and $0 in goodwill. Its cash balance stood at $2.70 million and cash and short-term investments were $2.70 million. The company’s total short-term debt was $8,871,700 while long-term debt stood at $0.
Kiromic Biopharma Inc’s total current assets stands at $4.71 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $6.62 million and inventory worth $0.
In 2024, Kiromic Biopharma Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Kiromic Biopharma Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.58
- 52-Week High
- $15.3
- 52-Week Low
- $1.43
- Analyst Target Price
- $
Kiromic Biopharma Inc stock is currently trading at $1.58 per share. It touched a 52-week high of $15.3 and a 52-week low of $15.3. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $2.33 and 200-day moving average was $4.24 The short ratio stood at 0.93 indicating a short percent outstanding of 0%.
Around 390.8% of the company’s stock are held by insiders while 6850% are held by institutions.
Frequently Asked Questions About Kiromic Biopharma Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Kiromic BioPharma, Inc., an artificial intelligence driven allogeneic cell therapy company, engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1, an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1, an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings, Inc. and Longwood University, as well as a research and development collaboration agreement with Molipharma, S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic, Inc. and changed its name to Kiromic BioPharma, Inc. in December 2019. Kiromic BioPharma, Inc. was founded in 2006 and is headquartered in Houston, Texas.